Leerink Partnrs Brokers Boost Earnings Estimates for PepGen

PepGen, Inc. (NASDAQ:PEPG) – Analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for shares of PepGen in a note issued to investors on Wednesday, November 12th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($2.74) per share for the year, up from their previous estimate of ($2.76). The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for PepGen’s Q4 2025 earnings at ($0.60) EPS, Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($2.96) EPS and FY2027 earnings at ($3.46) EPS.

Several other research firms have also recently commented on PEPG. HC Wainwright lifted their price target on PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Guggenheim reissued a “buy” rating and issued a $6.00 target price on shares of PepGen in a research report on Wednesday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of PepGen in a report on Wednesday, October 8th. Stifel Nicolaus upped their price target on shares of PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, Wedbush increased their price target on shares of PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, PepGen currently has a consensus rating of “Hold” and an average price target of $10.00.

PepGen Trading Up 12.9%

PepGen stock opened at $5.35 on Monday. The stock has a fifty day moving average price of $4.08 and a 200 day moving average price of $2.31. PepGen has a 52 week low of $0.88 and a 52 week high of $6.85. The firm has a market capitalization of $175.48 million, a P/E ratio of -1.90 and a beta of 1.95.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. grew its stake in PepGen by 87.7% during the third quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock worth $92,698,000 after buying an additional 9,375,000 shares during the period. Viking Global Investors LP raised its stake in shares of PepGen by 134.9% in the 3rd quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock valued at $16,089,000 after acquiring an additional 2,000,000 shares during the period. Commodore Capital LP acquired a new position in shares of PepGen during the 3rd quarter valued at $10,891,000. Vivo Capital LLC purchased a new stake in PepGen during the 3rd quarter worth $10,742,000. Finally, Laurion Capital Management LP boosted its position in PepGen by 133.4% during the 3rd quarter. Laurion Capital Management LP now owns 1,892,156 shares of the company’s stock worth $8,742,000 after purchasing an additional 1,081,395 shares during the period. 58.01% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other PepGen news, major shareholder Science Enterprises Plc Oxford bought 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 30th. The stock was purchased at an average price of $3.20 per share, with a total value of $640,000.00. Following the transaction, the insider owned 4,955,388 shares in the company, valued at $15,857,241.60. This trade represents a 4.21% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.60% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.